A Tumor-Agnostic NTRK (TRK) Inhibitor.

EPPIcenter Seminar: Leah Katzelnick- Immune Interactions: Dengue, Zika and other coronaviruses

Mosquito-borne flaviviruses infect hundreds of millions of people globally each year and cause a spectrum of life-threatening diseases, including hemorrhagic fevers, encephalitis, and severe congenital abnormalities. There are still no licensed, broadly protective vaccines against two of the most important flaviviruses: dengue virus and Zika virus. Dengue viruses 1-4 are challenging vaccine targets because sub-protective vaccines can increase risk of Dengue Hemorrhagic Fever/Dengue Shock Syndrome, the disease dengue vaccines are designed to prevent. The only licensed dengue vaccine to date significantly increases risk of severe dengue disease in those without a prior dengue virus exposure. Zika viruses emerged across the Americas in 2014-2017, causing major pandemics and congenital Zika syndrome, making development of a Zika vaccine a high priority.

Leah C. Katzelnick, PhD, MPH is a Stadtman Investigator, an NIH Distinguished Scholar in the Laboratory of Infectious Diseases, and Chief of the Viral Epidemiology and Immunity Unit of the NIAID. Her work focuses on immunologically complex diseases caused by flaviviruses, including dengue and Zika viruses, as well as coronaviruses. They collaborate with research teams to study determinants of disease in longitudinal cohort and vaccine studies in Nicaragua, Thailand, Ecuador, the Philippines, and other sites. To address questions about virus antigenicity, host protective immunity, and population-level viral transmission dynamics, they use biologically relevant immunological assays and diverse computational and epidemiological methods to measure and evaluate the role of immunity in protection against disease in human cohort studies.

Dr. Katzelnick pursued a PhD studying antigenic variation among dengue viruses at the University of Cambridge and the National Institutes of Health as an NIH OxCam Scholar and Gates Cambridge Scholar. After receiving her Ph.D. in 2016, she conducted her postdoctoral work at UC Berkeley and University of Florida on determinants of dengue and Zika disease, spending a year in Ecuador and Nicaragua to work closely with research teams conducting longitudinal cohort studies. 

Join the EPPIcenter in welcoming Leah C. Katzelnick as a seminar speaker.

The EPPIcenter at UCSF aims to advance the understanding of infectious diseases to reduce global morbidity and mortality. We believe that the greatest success in the fight against infectious diseases will come through a highly interdisciplinary, systems epidemiology approach, connecting traditionally siloed theoretical work, technology development, generation and collection of empiric data, and analysis using statistical and mathematical modeling. 

Access to cost information. Comment on "Availability of consumer prices from US hospitals for a common surgical procedure".

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

Nonviral liver disease is the leading indication for liver transplant in the United States in persons living with human immunodeficiency virus.

Intravenous regadenoson with aminophylline reversal is safe and equivalent to intravenous adenosine infusion for fractional flow reserve measurements.

A defective viral genome strategy elicits broad protective immunity against respiratory viruses.

Promotores' perspectives on the virtual adaptation of a hereditary breast cancer education program.

The aging of the heart and blood vessels: a consideration of anatomy and physiology in the era of computed tomography, magnetic resonance imaging, and positron emission tomographic imaging methods with special consideration of atherogenesis.

Study protocol for a cluster randomised controlled factorial design trial to assess the effectiveness and feasibility of reactive focal mass drug administration and vector control to reduce malaria transmission in the low endemic setting of Namibia.

Low income, community poverty and risk of end stage renal disease.

Predictors of Variation in Neurosurgical Supply Costs and Outcomes Across 4904 Surgeries at a Single Institution.

Welcome Dr. Jacklyn Katz to the Division of Geriatrics

Dr. Jacklyn Katz received her MD from the Temple University School of Medicine and most recently worked as Staff Physician at On Lok PACE before coming to UCSF.  Dr. Katz is passionate about geriatric medicine and dually boarded in both Geriatric and Internal Medicine.  She completed her Internal Medicine Residency at California Pacific Medical Center (CPMC) and her Geriatric Medicine Fellowship at UCLA.  Dr. Katz’s education and training has allowed her the opportunity to work with individuals from many different backgrounds, especially those who are underserved.  She recognizes the systemic healthcare system failure to provide equitable care to those individuals and actively works to alleviate those inadequacies as a member of the healthcare community.  As a leader in her field, Dr. Katz hopes to continue to address insufficiencies in our healthcare system and advocate for more diversity in the field of medicine such as hiring physicians who speak multiple languages or who are culturally congruent to a patient population.  Some of Dr. Katz’s leadership roles include serving as the Rotation Site Director for CPMC Internal Medicine Residents, as well as co-creating and contributing to the CPMC Internal Medicine Residency Blog.  In her new role at UCSF, Dr. Katz will primarily work in the UCSF Center for Geriatric Care and UCSF Geriatrics Inpatient Services at Moffitt-Long Hospital, but also providing on-call coverage for Care at Home.  Additionally, Dr. Katz will be collaborating with other faculty and providers on her academic work and will be involved in projects that are consistent with our Division’s mission of improving the care of older adults.  Welcome Dr. Katz!

Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome.

Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267.